By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exagen Diagnostics has agreed to buy the diagnostics business of Cypress Bioscience for up to $8 million in upfront and milestone payments.

Under the terms of the agreement announced Friday after the close of the market, Exagen will pay $4 million upfront, split into two separate payments 24 months apart, Cypress said in a statement. Exagen will also make milestone payments totaling up to $4 million and pay a 10 percent royalty to Cypress on defined product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.